Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They reported that 10 out of 12 had a good reaction. And they are cautiously optimistic.
This is no holy grail (yet)
He's a flipper
Why not a Nobel for Vamvakides?
Lets keep it real and both feet on the ground please! We have (good) data on 12 patients. Lets await further
Yes you are fully right Drano
We need to keep our feet on the ground and heads cool
This is what I said:
The combotrial is a p2b and not a p3, hence the population is a lot smaller but still designed to be statistically significant.
p2b is statistically significant, that has been said on multiple presentations. And as the p2b is an open label, there will be interim data release. Thas has also been said on multiple presentations.
To pre-empt your next question: go back, listen to the presentations, and you will hear it.
Contact dr Algazi, he is the lead
I have no issues to that regard but thanks for your concerns
Lets await interim p2b results and see if their hypotheses is correct
Who cuts short is of no importance to me as an investor. The message it sends is
My experience from ONCS: their institutional funds required 5$ pps so they did RS.
Maybe other tutes have lower thresholds. Surely hope we get there organically
Next goal should be an uplisting to get more exposure.
I don't care what others say or do or claim. Ofcourse a p3 will be required, but the p2 and even the p3 can be cut short by fda if the results are really good. Key word is 'can be'. Time will tell
The combotrial is a p2b and not a p3, hence the population is a lot smaller but still designed to be statistically significant.
All we need is prove the concept works. Why waist money to test the concept with hundreds of patients.
If the concept works then yes we will go into a p3 with multiple hundreds
Stay tuned for the annual shareholders meeting next Friday.
Carefull listeners will surely find interesting information.
OncoSec to Webcast Annual Meeting of Stockholders
No not in 2 months, but as in multiple months
The trial is not blinded, so data will be released a long the way. Go back to listen to Dr Pierce speaking in June. Its all there.
Last presentation made mentions that interim results will be released on combination trial, H&N, TNBC and extension study.
I feel like a broken record.
Bull
Significant data will be available in a couple of months as the trial is open designed, and by the way also statiscally significant
Noise can come from multiple sources
Yes it is good that we closed above the 50day average. As for gain, he who does not appreciate the small is not worthy of the big
Interim data will be available in a couple of months. That will drive the share price.
whats even more helpful if we all share our own due diligence and create a fountain of Oncosec wisdom!
pity you didn't buy at .46 earlier this week
well we wouldn't want to get our facts mixed up do we.
So the combination trial has started and is enrolling. In the next couple of months we will get several interim data:
1) combination trial
2) extension trial
3) Head and neck
4) tripple negative breast
Not it was not promised 8 months ago. It was announced.
Oh yeah it's easy piezy to copy a device that goes anywhere into the body to electroporate the administered IL-12. Sure, why not. sigh
Correction: the trial is not 8 months late. It was announced 8 months ago. At the time it was NOT said that it would enroll immediately. Hence one cannot conclude the delay is 8 months.
It is currently open for enrollment
At the risk of sounding like a broken record: we will not have to wait 2 years for data as it is an open trial.
Sorry but relevance to Anavex? Go private or tripadvisor
And you think someone on here gives any credibility to your postings?
Adam Freakenstein has been bashing BIIB on twitter
But lets hope it will be an organic one!
Interviewer Kanak Kanti De seems either to be deaf or learning impaired. How many times can Missling say there are no patent issues???
Well it was already obvious that you are trying to talk the pps lower to get in
Read the pr, do your research and then come back
Oh my nobody realized that, shit now we should all dump our shares so you can get in cheaper
Go back and read the pr and do your dd. Total patient size is 36, this was initital data
I am questioning what your expectations are as you sound dissappointed in the patient size
Its a p2 study, you were expecting hundreds?
And the good thing is that Keytruda (and Opdivo) gets approved in more and more cancer types both in the US and EU
Expanded market opportunities for Oncosec, especially when the new electroporation device, that can go anywhere in the body, will be available
But again all hinges on the results of the current combination trial, led by USCF
it's not because you have one white swan that you can automacally deduct that all swans are white.
So sure universities are not always efficient in using resources, but one cannot deduct from that the USCF trial with Merck's Keytruda and Oncosec IL-12 is a waiste
For the savvy investor that would like to have a recap on what cancer immmunotherapy is all about, go listen to the webcast from July 21st
Dr Pierce, our chief scientific officer, is very informative:
https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=1012702&sessionid=1&key=07765F5E788879107CB465823598E135&partnerref=SPONSOR_ONCOSEC_1507_BPDEALMAKERS&sourcepage=register
Even if I would agree on the mysterious removal of the CFO, which is NOT at all the case as she simply resigned and all other reasons are merely speculation without facts to back it up, this is not at all instrumental in the big scheme of things that Oncosec has going on.
I will focus on the combination trial with Merck's Keytruda, that is enrolling patients. This is were the real value drivers will be for us savvy investors.
Thats the reason I've sold: a dying volume. In the absence of news I see it bleed off again.
Oh you are quite right, it sounds really great that the patients and their caretakers are already asking to extend the b phase of the study. It means that those taking the medication actually know that it works!
You are quite right, and for those readers not fully in the loop: the combination trial with Merck's anti-pd1 is now actively enrolling. It is an open trial so expect news and data along the way.
As a sidenote, Keytruda has now been approved in the EU for 1st line treatment in advanced melanoma
Seriously, do a reality check! You are setting yourself up for dissappointment.
Take it one step at a time.